学位论文 > 优秀研究生学位论文题录展示

肝支持系统治疗肝衰竭

作　者: 张春裕
导　师: 唐国都
学　校: 广西医科大学
专　业: 消化内科
关键词: Liver support devices Liver failure
分类号: R575.3
类　型: 硕士论文
年　份: 2007年
下　载: 32次
引　用: 0次
阅　读: 论文下载
 

内容摘要


Despite the progress made in the intensive care treatment, liver failure is still associated with a high mortality, liver transplantation is the effective form of treatment that allows better patient outcome. Nonetheless, there is organ shortage and there is a need for liver support devices (LSD) that can effectively manage liver failure to bridge waitlist patients to transplant or regeneration whenever possible.At present, the development of LSD has been approached in two ways. Artificial LSD is based on detoxification functions using membranes and adsorbents which can remove the putative toxins associated with liver failure. The other is bioartificial LSD, are based on the use of living hepatocytes with either human hepatocytes or porcine hepatocytes which aim to provide the synthetic functions of the normal liver. However, in clinical practices often use a combination of devices from both.

全文目录


Contents  3-5
List of abbreviation  5-6
Abstract  6-7
Introduction  7-8
Liver support devices  8-14
Liver support devices development  14-18
Theories and methods of liver support devices  18-19
Artificial LSD  19-23
  1. Hemodialysis and Hemofiltration  19-20
  2. Exchange transfusion and Plasma exchange (Plasmapheresis)  20-21
  3. Hemoperfusion and Plasma perfusion  21-23
Combination treatments  23-35
  1. Artificial liver support system (ALSS)  23-26
  2. Hemodiabsorption (Biologic-DT)  26-28
  3. Molecular absorbent recirculating system (MARS)  28-34
  4. Single pass albumin dialysis (SPAD)  34-35
Bioartificial LSD  35-48
  1. Cross-Hemodialysis and Cross-Circulation  35
  2. Extracorporeal whole liver perfusion (ECLP)  35-38
  3. Bioartificial liver support system (BAL support system)  38-40
  4.  40-44
    A. HepatAssist  40-42
    B. HepatixELAD  42-44
  5. There are a number of improvements to the present models that are in various phases of development. Some systems, in particular, should be mentioned.  44-48
    A. Modular extra liver support (MELS)  44-45
    B. Academic medical center bioartificial liver (AMC-BAL)  45
    C. Hybrid artificial liver support system (HALSS)  45-46
    D. Hybrid bioartificial liver (HBAL)  46-47
    E. Monsanto/St. Louis  47
    F. Regenerex/Minnesota  47-48
Indications for LSD treatment  48-49
Contraindications  49-50
Complications  50-51
Conclusions  51-53
Appendices  53-55
Acknowledgements  55-56
References  56-58

相似论文

  1. 微纤维相关蛋白4在肝纤维化组织中的表达和外周血浓度与肝病理分级的相关性研究,R575.2
  2. 甘草酸二铵脂质配位体对非酒精性脂肪肝炎大鼠的治疗作用及部分机制研究,R575.5
  3. 肝硬化患者血浆B型利钠肽水平与肝功能状态相关性探讨,R575.2
  4. 自体骨髓干细胞移植治疗乙肝肝硬化临床研究,R575.2
  5. 肝硬化肝性脑病的感染诱因及其部位分析,R575.2
  6. 大鼠肝再生与肝硬化发生的基因转录谱相关性及其意义研究,R575.2
  7. 大鼠肝再生与非酒精性脂肪肝发生的基因转录谱相关性及其意义研究,R575.5
  8. 应用FISH和LCSM技术对肝硬化患者肠道微生态的初步研究,R575.2
  9. MELD评分与血清总胆固醇水平评估失代偿期乙肝肝硬化患者预后的价值,R575.2
  10. ω-3多不饱和脂肪酸治疗非酒精性脂肪性肝病（NAFLD）的基础与临床研究,R575.5
  11. 血清胆碱酯酶、血小板、肝纤维化指标在HBV感染各阶段的临床意义,R575.2
  12. 内镜下套扎治疗食道静脉曲张的疗效及对门脉血流动力学影响的观察,R575.2
  13. 自体骨髓干细胞移植治疗失代偿期肝硬化的临床研究,R575.2
  14. 肝硬化患者血浆B型利钠肽水平与腹水、尿钠及尿钾排出量的关系探讨,R575.2
  15. 西南地区肝硬化失代偿的相关网络数据库的构建及临床研究,R575.2
  16. UDCA（优思弗）治疗脂肪性肝病的临床疗效观察,R575.5
  17. 小鼠再生肝抗GalN/LPS联合诱导急性肝损伤的UCP2作用研究,R575.3
  18. 急性肝衰竭小鼠肝组织内质网应激反应及Cyclin D1、HGF受体c-met表达和意义,R575.3
  19. 人外周血单个核细胞体外向肝样细胞诱导分化的研究,R575.3
  20. 人外周血干细胞向肝细胞转化的研究,R575.1
  21. 细菌性肝脓肿合并2型糖尿病的临床分析,R575.4

中图分类: > 医药、卫生 > 内科学 > 消化系及腹部疾病 > 肝及胆疾病 > 肝功能衰竭
© 2012 www.xueweilunwen.com